The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/500. Detects a band of approximately 98-100 kDa.
Use at an assay dependent concentration. PubMed: 18431404
Use at an assay dependent concentration. This antibody is ideal for activity measurement and screening of various PDE8B enzyme variants in sample.
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in specific signaling in the thyroid gland.
Abundantly expressed in the thyroid. Also very weakly expressed in brain, spinal cord and placenta. In the thyroid isoform 1 predominates, and isoforms 2 and 6 are also highly expressed. In the placenta isoforms 1 and 2 are expressed equally. In the brain isoform 2 predominates.
Defects in PDE8B are the cause of striatal degeneration autosomal dominant (ADSD) [MIM:609161]. It is a movement disorder affecting the striatal part of the basal ganglia and characterized by bradykinesia, dysarthria and muscle rigidity. These symptoms resemble idiopathic Parkinson disease, but tremor is not present.
Belongs to the cyclic nucleotide phosphodiesterase family. PDE8 subfamily. Contains 1 PAS (PER-ARNT-SIM) domain.
Composed of a C-terminal catalytic domain containing two putative divalent metal sites and an N-terminal regulatory domain.
Wilmot Roussel H et al. Identification of gene expression profiles associated with cortisol secretion in adrenocortical adenomas. J Clin Endocrinol Metab98:E1109-21 (2013).
Read more (PubMed: 23539725) »
Horvath A et al. A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex. Eur J Hum Genet16:1245-53 (2008).
Read more (PubMed: 18431404) »